InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2023-12-13 00:00:00 ET · period of report 2023-12-11 · accession 0001883850-23-000094 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-12-13 2023-12-11 REGN SCHLEIFER LEONARD S Pres, CEO, Bd. Co-COB, Dir F - Tax $844.09 -12.8K 374.4K -3% -$10.84M
D 2023-12-13 2023-12-11 REGN SCHLEIFER LEONARD S Pres, CEO, Bd. Co-COB, Dir M - OptEx — +25.2K 387.3K +7% —
D 2023-12-13 2023-12-11 REGN SCHLEIFER LEONARD S Pres, CEO, Bd. Co-COB, Dir M - OptEx — -25.2K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-12-11 F D 12,841 $844.09 374,429 D — —
2 Common Common Stock 2023-12-11 M A 25,155 — 387,270 D — — (F1) On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.
3 Derivative 2019 Performance Stock Units 2023-12-11 M D 25,155 — 0 D — · — to — 25,155 Common Stock (F1) On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.